Smith Group Asset Management’s United Therapeutics UTHR Stock Holding History

Smith Group Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-279,156	Closed	-$29.6M	–	492
2016 Q2	$29.6M	Sell	279,156 -1,034	-0.4%	-$115K	0.88%	41
2016 Q1	$31.2M	Buy	280,190 +5,504	+2%	+$696K	0.93%	40
2015 Q4	$43M	Buy	274,686 +226,710	+473%	+$33M	1.27%	25
2015 Q3	$6.3M	Sell	47,976 -152,000	-76%	-$24.4M	0.24%	92
2015 Q2	$34.8M	Sell	199,976 -30,380	-13%	-$5.47M	1.17%	25
2015 Q1	$39.7M	Sell	230,356 -30,900	-12%	-$4.71M	1.33%	15
2014 Q4	$33.8M	Buy	261,256 +190	+0.1%	+$24.5K	1.18%	21
2014 Q3	$33.6M	Buy	261,066 +1,560	+0.6%	+$161K	1.25%	16
2014 Q2	$23M	Hold	259,506	–	–	0.85%	51
2014 Q1	$24.4M	Buy	259,506 +94,900	+58%	+$9.71M	0.93%	49
2013 Q4	$18.6M	Hold	164,606	–	–	0.71%	67
2013 Q3	$13M	Hold	164,606	–	–	0.54%	73
2013 Q2	$10.8M	Buy	+164,606	New	+$10.6M	0.47%	80

Other funds holding UTHR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Smith Group Asset Management's UTHR Position: Q3 2016 in Review

Smith Group Asset Management sold out of United Therapeutics (UTHR) in Q3 2016, closing a stake of 279,156 shares — an estimated $29.6M sold.

Smith Group Asset Management first reported a position in UTHR in Q2 2013 and held it in 13 quarters. The position peaked at $43M in Q4 2015. 394 funds tracked by Wall St. Rank hold UTHR as of Q3 2016.

Smith Group Asset Management reported no remaining United Therapeutics position as of Q3 2016 after selling out during the quarter.
Smith Group Asset Management sold 279,156 United Therapeutics shares in Q3 2016, an estimated $29.6M.
Smith Group Asset Management first reported a position in United Therapeutics in Q2 2013 and held it in 13 quarters.
Smith Group Asset Management's United Therapeutics position peaked at $43M in Q4 2015.
394 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2016.

Based on Smith Group Asset Management's 13F filing for Q3 2016, filed 2 Nov 2016.